The headline EPS miss is noise from a non-cash impairment; the core results and raised guidance are the real signal. Traders should focus on the 11% core EPS growth and the raised full-year outlook for core operating margin (+90 to +190 bps) and core EPS growth (+12% to +15%). The $1.5B buyback authorization provides downside support. Monitor the Q3 2026 earnings call for updates on tariff refund realization and the PowerVision discontinuation's impact on R&D spend.
Price Chart
Executive Summary
Alcon reported Q2 2026 net sales of $2.8 billion, up 8% YoY (7% constant currency), driven by strong performance across Surgical and Vision Care segments. However, reported operating income collapsed to $11 million (from $247 million) and diluted EPS was $0.00 due to a $505 million non-cash impairment charge from discontinuing the PowerVision IOL programs. Core diluted EPS (non-IFRS) rose 11% to $0.84, and the company raised its full-year guidance for core operating margin and core diluted EPS growth, signaling underlying operational strength despite the one-time charge. The market should focus on the core results and raised guidance, which are positive, while the impairment is a non-cash item that does not affect cash flow or long-term objectives.
Key Facts
- Q2 2026 net sales of $2.8 billion, up 8% reported / 7% constant currency vs Q2 2025
- Reported diluted EPS of $0.00 vs $0.35 in Q2 2025, due to a $505 million non-cash impairment charge from discontinuing PowerVision IOL programs
- Core diluted EPS (non-IFRS) of $0.84, up 11% vs Q2 2025
- Core operating margin improved 150 bps to 20.6% (reported) / 160 bps (constant currency)
- Full-year 2026 guidance raised: core operating margin change now +90 to +190 bps (from +70 to +170 bps); core diluted EPS growth now +12% to +15% (from +10% to +13%)
- Net cash from operations of $928 million in H1 2026, up from $889 million in H1 2025
- Free cash flow of $693 million in H1 2026, up from $681 million
- Returned $538 million to shareholders YTD through dividends and share repurchases
- $1.5 billion share repurchase authorization approved in May 2026, with ~$1.2 billion remaining
- Terminated proposed acquisition of LENSAR, Inc. on March 16, 2026
Financial Impact
Q2 2026 net sales $2.8B (+8% YoY); reported operating income $11M (vs $247M); core operating income $574M (+17%); reported diluted EPS $0.00 (vs $0.35); core diluted EPS $0.84 (+11%); H1 2026 operating cash flow $928M (+$39M YoY); free cash flow $693M (+$12M YoY)
Risk Factors
- Tariff impact of $40M-$90M expected for FY 2026, with ongoing uncertainty from U.S. trade policy
- PowerVision program discontinuation may signal broader R&D pipeline risk or future impairment charges
- Continued softness in the cataract market could pressure Surgical consumables growth
- Foreign currency volatility could impact reported results, with expected +90 bps tailwind to sales growth in FY 2026
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001167379-26-000030 |
| Document: q22026pressrelease.htm | 0001167379-26-000030 |
| Document: alc-20260630.htm | 0001167379-26-000030 |
| Document: 0001167379-26-000030-index-headers.html | 0001167379-26-000030 |
| Document: 0001167379-26-000030-index.html | 0001167379-26-000030 |
| Document: 0001167379-26-000030.txt | 0001167379-26-000030 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | 6-K | $75.35 $68.43 | ▼ −9.18% | ▼ −8.12% | $63.72 (−15.43%) |
Jun 26, 2026 14w ago | Court Ruling | $67.80 $67.21 | ▼ −0.87% | ▼ −2.13% | $63.72 (−6.02%) |
Jun 26, 2026 14w ago | Court Ruling | $67.80 $67.21 | ▼ −0.87% | ▼ −2.13% | $63.72 (−6.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access